Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
American Journal of Hematology|October 10, 2012
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profilesLaura Mosca, Pellegrino Musto, Katia Todoerti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2013
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemiaMarta Lionetti, Pellegrino Musto, Maria Teresa Di Martino, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Critical Reviews in Oncology/Hematology|January 3, 2021
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paperAlessandro Busca, Chiara Cattaneo, Elena De Carolis, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Critical Reviews in Oncology/Hematology|September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysisSara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
American Journal of Hematology|October 10, 2012
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profilesLaura Mosca, Pellegrino Musto, Katia Todoerti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2013
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemiaMarta Lionetti, Pellegrino Musto, Maria Teresa Di Martino, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Critical Reviews in Oncology/Hematology|January 3, 2021
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paperAlessandro Busca, Chiara Cattaneo, Elena De Carolis, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Critical Reviews in Oncology/Hematology|September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysisSara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Pageof 15